HR and breast carcinoma: In this randomized, double-blind trial, we evaluated the safety and efficacy of dovitinib plus fulvestrant compared with placebo plus fulvestrant in postmenopausal patients with HR+, HER2− advanced breast cancer that progressed during or after prior endocrine therapy.